SCHEMBL20535865

SCHEMBL20535865

COC(=O)c1cc2c(Oc3ccccc3)cc(Cl)cc2[nH]1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 11/20 0.73
XDH P47989 2/20 0.55
BRD4 O60885 1/20 0.49
ULK1 O75385 1/20 0.49
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
GRIN1 Q05586 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23709943 0.90 RHEB (0.60) RHEBXDHULK1CYP1A2CYP3A4
SCHEMBL23709772 0.87 RHEB (0.77) RHEBIDO1TDO2GRIN1KDM4E
SCHEMBL20536067 0.87 RHEB (0.81) RHEBIDO1TDO2GRIN1KDM4E
SCHEMBL23709746 0.86 RHEB (0.59) RHEBXDHULK1GRIN1GAA
SCHEMBL20535639 0.85 RHEB (0.55) RHEBXDHULK1GRIN1
SCHEMBL20536158 0.85 RHEB (1.00) RHEBIDO1TDO2GRIN1KDM4E
SCHEMBL30396582 0.83 XDH (0.59) RHEBXDHBRD4ULK1KDM4E
SCHEMBL24020832 0.83 ULK1 (0.53) RHEBULK1IDO1TDO2GRIN1
SCHEMBL30310577 0.83 ULK1 (0.53) RHEBULK1IDO1TDO2GRIN1
SCHEMBL20535455 0.82 RHEB (0.75) RHEBULK1GRIN1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885XDH 4335/4885BRD4 2112/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885XDH 3656/4885BRD4 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.